Study of new targeted therapies for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of pancreatic cancer (adenocarcinoma).
- You must have already tried at least one prior cancer treatment (like chemotherapy).
- Your tumor must have a specific genetic change called KRAS G12D.
- Cancer must be measurable (able to be seen on scans) and not removable by surgery.
- You must be in generally good health, with normal organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with other treatments for advanced pancreatic cancer. It aims to see if the combination can help people whose cancer has a specific genetic change called RAS mutation.
This study tests a new drug that targets a common genetic change (RAS) in pancreatic cancer, combined with other treatments. It aims to see if this combination is safe and effective for people whose cancer has advanced despite prior therapy.
This trial tests a new medicine (DN022150) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The combination may help shrink or slow the cancer better than chemotherapy alone.
This trial compares a new targeted pill (DN022150) with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12D gene change. It aims to see if the new drug works better at shrinking tumors and improving survival.
This trial tests an experimental drug for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
This trial tests a new combination of drugs (including an investigational immunotherapy and a targeted pill, plus standard chemotherapy) as the first treatment for pancreatic cancer that cannot be removed with surgery. It may help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.